Asenapine vs Loxapine (Adasuve)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Asenapine
Marketed by AbbVie and partners
NCT00212784 · Phase 3 · completed
This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.
Reported efficacy
Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint): Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint (unclear)
Result source: NCT00212771
Loxapine (Adasuve)
Marketed by Lee's Pharmaceutical and partners
NCT00628589 · Phase 3 · completed
The trial randomly assigned 344 participants to inhaled loxapine 5 mg, loxapine 10 mg, or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical agitation measure was significantly improved with both loxapine doses compared with placebo (p=0.0004 and p<0.0001).
Reported efficacy
Change in PANSS-EC From Baseline (Baseline and 2 hours): Change in PANSS-EC From Baseline (Baseline and 2 hours): Inhaled Loxapine 5 mg -8.1 units on a scale (Standard Deviation 5.17) | Inhaled Loxapine 10 mg -8.6 units on a scale (Standard Deviation 4.37) vs Inhaled Placebo -5.5 units on a scale (Standard Deviation 4.92) (met)
Result source: NCT00628589
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Asenapine | Loxapine (Adasuve) |
|---|---|---|
| PANSS total, change | -25.5 vs -17.8−7.7 vs placeboNCT0119025418 other results
| —Not reported |
| CGI-S, change | -1.3 vs -0.8−0.5 vs placeboNCT0119025417 other results
| —Not reported |
| PANSS response | 39.3% vs 20.7%+18.6 vs placeboNCT010981101 other result
| —Not reported |
| PSP, change | —Not posted · NCT00212771 | —Not reported |
| Relapse (% of patients) | —Not posted · NCT00212771 | —Not reported |
PANSS total, change
- Asenapine
- -25.5 vs -17.8−7.7 vs placeboNCT01190254
18 other results
- -21.7 vs -16.2 NCT01617187
- -12.2 vs -0.9 NCT01098110
- -14.2 vs -0.9 NCT01098110
- -23.7 vs -17.8 NCT01190254
- -17.4 vs -16.2 NCT01617187
- -19 vs -15.4 NCT01617187
- -17.1 vs -15.5 NCT01617187
- -14.8 vs -13.2 NCT01617187
- -12.5 vs -10.7 NCT01617187
- -9.1 vs -7.1 NCT01617187
- -4.9 vs -4.8 NCT01617187
- -17 vs -15.4 NCT01617187
- -12.3 vs -15.5 NCT01617187
- -12 vs -13.2 NCT01617187
- -9.9 vs -10.7 NCT01617187
- -7.2 vs -7.1 NCT01617187
- -4 vs -4.8 NCT01617187
- -21 vs -27.5 NCT00212784
- Loxapine (Adasuve)
- —Not reported
CGI-S, change
- Asenapine
- -1.3 vs -0.8−0.5 vs placeboNCT01190254
17 other results
- -1.2 vs -1 NCT01617187
- -0.7 vs -0.2 NCT01098110
- -1.1 vs -0.8 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -0.8 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.2 vs -0.2 NCT01617187
- -0.8 vs -0.2 NCT01098110
- -1.1 vs -0.8 NCT01190254
- -0.9 vs -1 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -0.7 vs -0.8 NCT01617187
- -0.6 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.1 vs -0.2 NCT01617187
- Loxapine (Adasuve)
- —Not reported
PANSS response
- Asenapine
- 39.3% vs 20.7%+18.6 vs placeboNCT01098110
1 other result
- 43.8% vs 20.7% NCT01098110
- Loxapine (Adasuve)
- —Not reported
PSP, change
- Asenapine
- —Not posted · NCT00212771
- Loxapine (Adasuve)
- —Not reported
Relapse (% of patients)
- Asenapine
- —Not posted · NCT00212771
- Loxapine (Adasuve)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. Asenapine: 6 of 6 rows · Loxapine (Adasuve): 5 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Asenapine | Loxapine (Adasuve) |
|---|---|---|
| CGI-I responder rate · % of participants | 60.1% (n=104) vs 54.7% (n=100) placebo @ 8.3wk5.0 mg BIDa,b,c,d NCT01190254 · Phase 3 · registry result, not featured evidence show 1 more dose47.1% (n=96) vs 54.7% (n=100) placebo @ 8.3wk2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence | 67% (n=112) vs 35.7% (n=115) placebo @ 0.0119wk*10 mga,b,c,d NCT00628589 · Phase 3 · monotherapy · converted to % from 75 Participants as posted show 1 more dose56.9% (n=116) vs 35.7% (n=115) placebo @ 0.0119wk*5 mg NCT00628589 · Phase 3 · monotherapy · converted to % from 66 Participants as posted |
| CGI-I absolute value · score | 2.5 vs 3.1 placebo score @ 8wk5.0 mg BIDa,b,c,e NCT01190254 · Phase 3 · registry result, not featured evidence show 1 more dose2.8 vs 3.1 placebo score @ 8wk2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence | 2.1 vs 2.8 placebo score @ 0.0119wk10 mga,b,c,e NCT00628589 · Phase 3 · monotherapy show 1 more dose2.3 vs 2.8 placebo score @ 0.0119wk5 mg NCT00628589 · Phase 3 · monotherapy |
| Dropout rate | 44.4%5 mg twice dailyf NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results16.7%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 54.8%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 1%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 49.7% NCT01244828 · Phase 3 · registry result, not featured evidence 35.2%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 40.1%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 50%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.9%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 17.3%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 33.7% NCT00174265 · Phase 3 · registry result, not featured evidence 50.4% NCT00145496 · Phase 3 · registry result, not featured evidence 30.4% NCT00150176 · Phase 3 · registry result, not featured evidence 15.7% NCT00265343 · Phase 3 · registry result, not featured evidence 67.7% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence 33.3%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 25%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 2.7%10 mgf NCT00628589 · Phase 3 · monotherapy show 8 more results1.7%5 mg NCT00628589 · Phase 3 · monotherapy 2.4%10 mg NCT00369577 · Phase 2 · registry result, not featured evidence 0%5 mg NCT00369577 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%1.25 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%0.625 mg NCT00444028 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 22.2%5 mg twice dailyf NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 22.3%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 0%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 23.6% NCT01244828 · Phase 3 · registry result, not featured evidence 17%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 17.6%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 0%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 5.1%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 7.5%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 6.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 8.1% NCT00174265 · Phase 3 · registry result, not featured evidence 17.2% NCT00145496 · Phase 3 · registry result, not featured evidence 8.2% NCT00150176 · Phase 3 · registry result, not featured evidence 7.5% NCT00265343 · Phase 3 · registry result, not featured evidence 11.8% NCT00156065 · Phase 3 · registry result, not featured evidence —5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | —10 mgf NCT00628589 · Phase 3 · monotherapy show 8 more results—5 mg NCT00628589 · Phase 3 · monotherapy —10 mg NCT00369577 · Phase 2 · registry result, not featured evidence —5 mg NCT00369577 · Phase 2 · registry result, not featured evidence —10 mg NCT00444028 · Phase 1 · registry result, not featured evidence —5 mg NCT00444028 · Phase 1 · registry result, not featured evidence —2.5 mg NCT00444028 · Phase 1 · registry result, not featured evidence —1.25 mg NCT00444028 · Phase 1 · registry result, not featured evidence —0.625 mg NCT00444028 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 0%5 mg twice dailyf NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 20.4%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 4.4%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 5.2%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 8.9% NCT01244828 · Phase 3 · registry result, not featured evidence 5.7%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 2.8%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 12.5%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 3.6%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 2.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 3.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 4.7% NCT00174265 · Phase 3 · registry result, not featured evidence 12.3% NCT00145496 · Phase 3 · registry result, not featured evidence 3.1% NCT00150176 · Phase 3 · registry result, not featured evidence 6.7% NCT00265343 · Phase 3 · registry result, not featured evidence 14.1% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 0.9%10 mgf NCT00628589 · Phase 3 · monotherapy show 8 more results0%5 mg NCT00628589 · Phase 3 · monotherapy 2.4%10 mg NCT00369577 · Phase 2 · registry result, not featured evidence 2.2%5 mg NCT00369577 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%1.25 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%0.625 mg NCT00444028 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 5 mg twice dailyf daytime drowsiness 22.2% NCT01549041 · Phase 4 · registry result, not featured evidence show 19 more results10 mg daily in the evening daytime drowsiness 0% NCT01549041 · Phase 4 · registry result, not featured evidence 5/10 mg BID nasopharyngitis 21.7% schizophrenia 10.8% somnolence 10.8% NCT01142596 · Phase 3 · registry result, not featured evidence 5 mg BID insomnia 15% (placebo 13.9%) headache 8.8% (placebo 2%) anxiety 7.1% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence 2.5 mg BID headache 10.3% (placebo 2%) insomnia 9.3% (placebo 13.9%) anxiety 7.2% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence nasopharyngitis 21% somnolence 12.7% weight increased 12.7% NCT01244828 · Phase 3 · registry result, not featured evidence 5 mg BID akathisia 11.4% (placebo 5.2%) hypoaesthesia oral 10.9% (placebo 3.4%) insomnia 9.7% (placebo 12.1%) NCT01098110 · Phase 3 · registry result, not featured evidence 10 mg BID schizophrenia 13.8% (placebo 24.1%) somnolence 12.2% (placebo 1.7%) akathisia 10.5% (placebo 5.2%) NCT01098110 · Phase 3 · registry result, not featured evidence accidental overdose 12.5% acne 12.5% akathisia 12.5% NCT01190267 · Phase 3 · registry result, not featured evidence somnolence 14.8% headache 6.6% sedation 5.1% NCT01190267 · Phase 3 · registry result, not featured evidence 5.0 mg BID somnolence 17% (placebo 6.9%) sedation 11.3% (placebo 2%) insomnia 9.4% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence 2.5 mg BID somnolence 20.4% (placebo 6.9%) dizziness 7.1% (placebo 1%) headache 7.1% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence insomnia 10.6% weight increased 5.9% headache 2.4% NCT00174265 · Phase 3 · registry result, not featured evidence insomnia 17.6% somnolence 14.8% headache 13.5% NCT00145496 · Phase 3 · registry result, not featured evidence insomnia 20.1% (placebo 24.5%) somnolence 16% (placebo 17.2%) weight increased 14.4% (placebo 10.9%) NCT00150176 · Phase 3 · registry result, not featured evidence headache 5.2% influenza 5.2% schizophrenia 5.2% NCT00265343 · Phase 3 · registry result, not featured evidence insomnia 18.5% headache 10.9% parkinsonism 10.9% NCT00156065 · Phase 3 · registry result, not featured evidence 5 mg dystonia 66.7% dizziness 33.3% nausea 33.3% NCT01206517 · Phase 1 · registry result, not featured evidence 10 mg hypoaesthesia oral 50% dizziness 38.9% dysgeusia 38.9% NCT01206517 · Phase 1 · registry result, not featured evidence 2.5 mg sedation 33.3% dysgeusia 16.7% hypoaesthesia oral 16.7% NCT01206517 · Phase 1 · registry result, not featured evidence | 10 mgf dizziness 10.6% (placebo 9.6%) dysgeusia 10.6% (placebo 2.6%) sedation 10.6% (placebo 9.6%) NCT00628589 · Phase 3 · monotherapy show 8 more results5 mg sedation 12.9% (placebo 9.6%) dysgeusia 8.6% (placebo 2.6%) dizziness 5.2% (placebo 9.6%) NCT00628589 · Phase 3 · monotherapy 10 mg sedation 22% (placebo 14%) dysgeusia 17.1% (placebo 9.3%) headache 12.2% (placebo 2.3%) NCT00369577 · Phase 2 · registry result, not featured evidence 5 mg sedation 13.3% (placebo 14%) dizziness 11.1% (placebo 9.3%) dysgeusia 4.4% (placebo 9.3%) NCT00369577 · Phase 2 · registry result, not featured evidence 10 mg dizziness 75% (placebo 35.7%) dysgeusia 75% (placebo 0%) somnolence 75% (placebo 21.4%) NCT00444028 · Phase 1 · registry result, not featured evidence 5 mg dizziness 57.1% (placebo 35.7%) fatigue 42.9% (placebo 7.1%) dysgeusia 28.6% (placebo 0%) NCT00444028 · Phase 1 · registry result, not featured evidence 2.5 mg dizziness 50% (placebo 35.7%) nausea 50% (placebo 0%) dysgeusia 33.3% (placebo 0%) NCT00444028 · Phase 1 · registry result, not featured evidence 1.25 mg dizziness 25% (placebo 35.7%) dysgeusia 25% (placebo 0%) headache 25% (placebo 14.3%) NCT00444028 · Phase 1 · registry result, not featured evidence 0.625 mg dizziness 28.6% (placebo 35.7%) disturbance in attention 14.3% (placebo 7.1%) dysgeusia 14.3% (placebo 0%) NCT00444028 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 8.3 weeks versus 0.0119 weeks.
- eAssessment timepoints differ: 8 weeks versus 0.0119 weeks.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Asenapine
show 1 more result
show 1 more result
show 18 more results
show 17 more results
show 17 more results
show 2 more results
show 15 more results
show 15 more results
show 17 more results
show 17 more results
show 17 more results
show 17 more results
+ 32 further endpoints in the CSV export.
Loxapine (Adasuve)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Bipolar Disorder
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline
Asenapine
Marketed by AbbVie and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Loxapine (Adasuve)
Marketed by Lee's Pharmaceutical and partners
NCT04148963 · Phase 3 · status unknown
This Phase 3 trial randomly assigned agitated adults with schizophrenia or bipolar disorder to inhaled loxapine or inhaled placebo under quadruple-blind conditions, using change in the PANSS-EC agitation scale at 2 hours as the primary endpoint. No results have been posted, so this remains a well-designed, blinded, placebo-controlled trial whose findings are not yet known. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
No aligned efficacy figure on record for this race.
Results for Bipolar Disorder
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Loxapine (Adasuve): registry results are on file for Bipolar Disorder, but their comparison mappings are not yet available.
Available safety results
Asenapine
| Dropout rate | 33.3%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence show 6 more results—10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 25%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence show 6 more results—10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence |
| Serious AEs | —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence show 6 more results0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 10 mg hypoaesthesia oral 50% dizziness 38.9% dysgeusia 38.9% NCT01206517 · Phase 1 · registry result, not featured evidence show 2 more results5 mg dystonia 66.7% dizziness 33.3% nausea 33.3% NCT01206517 · Phase 1 · registry result, not featured evidence 2.5 mg sedation 33.3% dysgeusia 16.7% hypoaesthesia oral 16.7% NCT01206517 · Phase 1 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Loxapine (Adasuve)'s landscape